Alnylam Pharmaceuticals’ (ALNY) Market Perform Rating Reiterated at Leerink Swann
Leerink Swann reiterated their market perform rating on shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) in a research note published on Thursday. Leerink Swann currently has a $43.00 price target on the biopharmaceutical company’s stock.
Several other equities analysts have also commented on ALNY. Cowen and Company restated a buy rating and issued a $150.00 price objective on shares of Alnylam Pharmaceuticals in a report on Sunday, August 7th. Needham & Company LLC restated a buy rating and issued a $152.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, August 5th. Janney Montgomery Scott started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 28th. They issued a neutral rating and a $74.00 price objective on the stock. Jefferies Group set a $86.00 price objective on shares of Alnylam Pharmaceuticals and gave the company a buy rating in a report on Wednesday, September 28th. Finally, Goldman Sachs Group Inc. reaffirmed a neutral rating and issued a $65.00 target price (up from $63.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, August 10th. Eight analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $71.06.
Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 50.04 on Thursday. The stock’s market capitalization is $4.29 billion. Alnylam Pharmaceuticals has a one year low of $31.38 and a one year high of $109.10. The company’s 50-day moving average is $45.17 and its 200 day moving average is $60.61.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.14) by $0.07. Alnylam Pharmaceuticals had a negative net margin of 1,041.16% and a negative return on equity of 33.97%. The firm earned $13.70 million during the quarter, compared to analysts’ expectations of $9.14 million. During the same period last year, the company earned ($0.91) EPS. The business’s quarterly revenue was up 116.7% on a year-over-year basis. Equities analysts expect that Alnylam Pharmaceuticals will post ($4.77) EPS for the current year.
In related news, Director David E. I. Pyott bought 27,900 shares of the business’s stock in a transaction dated Thursday, October 13th. The stock was purchased at an average cost of $37.00 per share, for a total transaction of $1,032,300.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.00% of the stock is owned by company insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Dodge & Cox bought a new stake in Alnylam Pharmaceuticals during the second quarter worth $139,650,000. Bridger Management LLC purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $50,041,000. Slate Path Capital LP increased its position in Alnylam Pharmaceuticals by 56.6% in the first quarter. Slate Path Capital LP now owns 1,135,000 shares of the biopharmaceutical company’s stock valued at $71,244,000 after buying an additional 410,000 shares in the last quarter. Deerfield Management Co. purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $18,645,000. Finally, Janus Capital Management LLC increased its position in Alnylam Pharmaceuticals by 908.8% in the second quarter. Janus Capital Management LLC now owns 358,122 shares of the biopharmaceutical company’s stock valued at $19,871,000 after buying an additional 322,622 shares in the last quarter. Hedge funds and other institutional investors own 85.20% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.